NMTC

NeuroOne Medical Technologies Corporation (NMTC) | Rumor.io

NeuroOne Medical Technologies

NMTC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,299

Bullish sentiment (50-day avg)38%

Price to earnings ratio-2.44

Market capitalization11.8M

Earnings per share-0.97

Dividend yield (TTM)—

Revenue (annual)9.1M

Net income (annual)-3.6M

Social

What share of all stock conversation is about NMTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 27

NeuroOne Medical Technologies Corporation has achieved significant milestones, including $2.0 million in fiscal Q3 product revenue, up 16% year over year, and received ISO 13485 certification, opening a path to international commercialization.
The company has successfully completed three large-animal StereoCED procedures, including combined drug delivery and brain recording, and is targeting human investigational launch by the end of the quarter.
NeuroOne's StereoCED platform has reached another important development milestone, with successful repeatability demonstrated across the procedures, providing confidence as the company progresses toward the planned launch of StereoCED for human investigational clinical studies later this quarter.

Generated by AI

Sentiment

Of the messages about NMTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% -40	71.95% -18.26
Bearish	100%	100%	100% +40	28.05% +18.26

Bullish· Mar 25

$NMTC has seen significant premarket volume, indicating potential heavy buying pressure and a possible breakout.
The company has made progress in commercialization, with recent FDA clearances and partnerships, which could lead to increased demand and a positive impact on the stock price.
$NMTC has a low market capitalization and float, making it a potentially volatile and explosive stock, with the possibility of a significant price increase in the near future.

Bearish· Sep 7

$NMTC's recent FDA approval has not provided the expected momentum, with the stock experiencing a "nice float clear break of $6.30" and "garbage" price action.
The company's dilution of 12.5 million shares at 1.00 and warrants for 1.75 for the uplisting from the OTC has led to a "sick liquidity trap idea" and "new bag holders deep".
$NMTC's stock has been "tanking like hell again" and is "dead cat" with a "worthless pile of shit" price action, making it a "risky stock" with no long-term opportunity.

Generated by AI

Topics

Of the messages about NMTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	78.99%
Analysts	—	0%	0%	2.72%
Earnings	—	0%	0%	7%
Controversies	—	0%	0%	0.39%
Macro	—	0%	0%	1.17%
Technical Analysis	—	0%	0%	9.73%

Announcements· Aug 27

NeuroOne Medical Technologies Corporation ($NMTC) reported $2.0 million in fiscal Q3 product revenue, up 16% year over year, and received ISO 13485 certification, opening a path to international commercialization.
NeuroOne completed three large-animal StereoCED procedures, including combined drug delivery and brain recording, which represents a first in the field of convection-enhanced delivery.
The company expects its StereoCED platform to be available by fiscal year-end on September 30, 2026, for animal research and FDA IDE-approved studies, with the first patient in its OneRF brain-ablation post-market registry also targeted by the end of September.

Technical Analysis· Mar 25

$NMTC has seen significant volume increases, with some days reaching 4X the daily average, indicating heavy accumulation.
The stock has been testing resistance levels around $1.35, with some successful breaks and others failing, suggesting a potential breakout is imminent.
Technical analysis suggests that a break above $1.35 could send the stock towards $1.50 or higher, with key resistance points at $1.33 and $1.48.

Generated by AI

Community

Of the messages about NMTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	40%	33.33%	52.46%
Newcomers	0%	60%	66.67%	47.54%

Regulars· Dec 22

NeuroOne Medical Technologies Corporation has filed form 424B5, indicating a potential IPO or capital raise, and has been short sale restricted.
The company has reported its fiscal fourth quarter and full fiscal year 2022 financial results, with a press release available on December 22.
NeuroOne Medical Technologies has filed form 10-K and form 8-K, detailing its financial results and operations, with breaking news available 45 seconds earlier than the usual delay.

Newcomers· Aug 27

NeuroOne Medical Technologies has reported $2.0 million in fiscal Q3 product revenue, a 16% year-over-year increase, driven mainly by OneRF products.
The company has received ISO 13485 certification, opening a path to international commercialization.
NeuroOne's StereoCED platform has reached another important development milestone, with the successful completion of three separate large-animal procedures, demonstrating the ability to deliver a study agent directly into targeted brain tissue and record intracranial electrophysiological activity.

Generated by AI

Agreement Covers Key Southern California Counties Including Los Angeles Metro as NeuroOne Broadens Commercial Access in Key U.S. MarketsEDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal

13d agoYahoo Finance

NeuroOne at Moody Capital conference: thin-film platform aims for growth

20d agoInvesting.com

NeuroOne CBO David Wambeke buys $66,999 in company stock

22d agoInvesting.com

NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform

Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED(TM) Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED(TM) Revenue Expected to be Recognized in the Current Fiscal Quarter ...

1mo agoYahoo Finance

NeuroOne (NMTC) Q3 2026 Earnings Call Transcript

Detailed price information for Neuroone Medical Technologies Corp (NMTC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Neuroone Medical earnings missed by $0.10, revenue fell short of estimates

1mo agoInvesting.com

Also Discussed

Investors talking about NMTC also mention

#	Name	Attention
1	Coeptis Therapeutics, Inc.COEP	0%new
2	OKYO Pharma Ltd.OKYO	0%0
3	RenovoRx, Inc.RNXT	0%0
4	Immix Biopharma, Inc.IMMX	0.03%+0.03
5	Minerva Surgical Inc.UTRS	0%0
6	Zimmer Biomet Holdings, Inc.ZBH	0%0
7	First Capital IncFCAP	0%0
8	BTCY - Biotricity, Inc.	——
9	Heritage Global Inc.HGBL	0%0
10	Genprex Inc. Common StockGNPX	0%0

NeuroOne Medical Technologies Corporation

Healthcare
Medical Devices

NeuroOne Medical Technologies Corporation is a medical technology company focused on diagnostic and therapeutic solutions for neurological disorders. The company develops and commercializes thin-film electrode technology for continuous electroencephalogram and stereoelectroencephalography recording, along with minimally invasive systems for brain ablation, stimulation, and drug delivery. Its product portfolio includes Evo cortical electrodes, Evo sEEG electrodes, and OneRF ablation systems designed for neurosurgery, neurology, and pain management applications. NeuroOne Medical Technologies Corporation serves clinical settings that treat conditions such as epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremor, and chronic pain. Based in Eden Prairie, Minnesota, the company plays a specialized role in the neurotechnology market by supporting more precise monitoring and treatment options for patients with complex brain and nerve-related disorders.

Website

Location

7599 Anagram Drive

Eden Prairie, MN, 55344

United States

Social

What share of all stock conversation is about NMTC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 27

NeuroOne Medical Technologies Corporation has achieved significant milestones, including $2.0 million in fiscal Q3 product revenue, up 16% year over year, and received ISO 13485 certification, opening a path to international commercialization.
The company has successfully completed three large-animal StereoCED procedures, including combined drug delivery and brain recording, and is targeting human investigational launch by the end of the quarter.
NeuroOne's StereoCED platform has reached another important development milestone, with successful repeatability demonstrated across the procedures, providing confidence as the company progresses toward the planned launch of StereoCED for human investigational clinical studies later this quarter.

Generated by AI

Sentiment

Of the messages about NMTC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% -40	71.95% -18.26
Bearish	100%	100%	100% +40	28.05% +18.26

Bullish· Mar 25

$NMTC has seen significant premarket volume, indicating potential heavy buying pressure and a possible breakout.
The company has made progress in commercialization, with recent FDA clearances and partnerships, which could lead to increased demand and a positive impact on the stock price.
$NMTC has a low market capitalization and float, making it a potentially volatile and explosive stock, with the possibility of a significant price increase in the near future.

Bearish· Sep 7

$NMTC's recent FDA approval has not provided the expected momentum, with the stock experiencing a "nice float clear break of $6.30" and "garbage" price action.
The company's dilution of 12.5 million shares at 1.00 and warrants for 1.75 for the uplisting from the OTC has led to a "sick liquidity trap idea" and "new bag holders deep".
$NMTC's stock has been "tanking like hell again" and is "dead cat" with a "worthless pile of shit" price action, making it a "risky stock" with no long-term opportunity.

Generated by AI

Topics

Of the messages about NMTC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	78.99%
Analysts	—	0%	0%	2.72%
Earnings	—	0%	0%	7%
Controversies	—	0%	0%	0.39%
Macro	—	0%	0%	1.17%
Technical Analysis	—	0%	0%	9.73%

Announcements· Aug 27

NeuroOne Medical Technologies Corporation ($NMTC) reported $2.0 million in fiscal Q3 product revenue, up 16% year over year, and received ISO 13485 certification, opening a path to international commercialization.
NeuroOne completed three large-animal StereoCED procedures, including combined drug delivery and brain recording, which represents a first in the field of convection-enhanced delivery.
The company expects its StereoCED platform to be available by fiscal year-end on September 30, 2026, for animal research and FDA IDE-approved studies, with the first patient in its OneRF brain-ablation post-market registry also targeted by the end of September.

Technical Analysis· Mar 25

$NMTC has seen significant volume increases, with some days reaching 4X the daily average, indicating heavy accumulation.
The stock has been testing resistance levels around $1.35, with some successful breaks and others failing, suggesting a potential breakout is imminent.
Technical analysis suggests that a break above $1.35 could send the stock towards $1.50 or higher, with key resistance points at $1.33 and $1.48.

Generated by AI

Community

Of the messages about NMTC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	40%	33.33%	52.46%
Newcomers	0%	60%	66.67%	47.54%

Regulars· Dec 22

NeuroOne Medical Technologies Corporation has filed form 424B5, indicating a potential IPO or capital raise, and has been short sale restricted.
The company has reported its fiscal fourth quarter and full fiscal year 2022 financial results, with a press release available on December 22.
NeuroOne Medical Technologies has filed form 10-K and form 8-K, detailing its financial results and operations, with breaking news available 45 seconds earlier than the usual delay.

Newcomers· Aug 27

NeuroOne Medical Technologies has reported $2.0 million in fiscal Q3 product revenue, a 16% year-over-year increase, driven mainly by OneRF products.
The company has received ISO 13485 certification, opening a path to international commercialization.
NeuroOne's StereoCED platform has reached another important development milestone, with the successful completion of three separate large-animal procedures, demonstrating the ability to deliver a study agent directly into targeted brain tissue and record intracranial electrophysiological activity.

Generated by AI

NeuroOne Medical Technologies

Social

Aug 27

Bullish· Mar 25

Bearish· Sep 7

Announcements· Aug 27

Technical Analysis· Mar 25

Regulars· Dec 22

Newcomers· Aug 27

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

NeuroOne at Moody Capital conference: thin-film platform aims for growth

NeuroOne CBO David Wambeke buys $66,999 in company stock

NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform

NeuroOne (NMTC) Q3 2026 Earnings Call Transcript

Neuroone Medical earnings missed by $0.10, revenue fell short of estimates

Also Discussed

NeuroOne Medical Technologies Corporation

Company Information

Location

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

NeuroOne at Moody Capital conference: thin-film platform aims for growth

NeuroOne CBO David Wambeke buys $66,999 in company stock

NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform

NeuroOne (NMTC) Q3 2026 Earnings Call Transcript

Neuroone Medical earnings missed by $0.10, revenue fell short of estimates

Also Discussed

Social

Aug 27

Bullish· Mar 25

Bearish· Sep 7

Announcements· Aug 27

Technical Analysis· Mar 25

Regulars· Dec 22

Newcomers· Aug 27